Matches in SemOpenAlex for { <https://semopenalex.org/work/W2294409638> ?p ?o ?g. }
- W2294409638 endingPage "20208" @default.
- W2294409638 startingPage "20193" @default.
- W2294409638 abstract "// Haiyong Wang 1, 2, * , Chenyue Zhang 1, 3, * , Litao Xu 1, 3 , Kun Zang 1, 3 , Zhouyu Ning 1, 3 , Feng Jiang 4 , Huiying Chi 5 , Xiaoyan Zhu 1, 3 , Zhiqiang Meng 1, 3 1 Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China 2 Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Jinan, 250117, China 3 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China 4 Department of Integrative Oncology, Zhucheng Hospital of TCM, Zhucheng 262200, China 5 Shanghai Geriatric Institute of Chinese Medicine, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200031, China * These authors contributed equally to this work Correspondence to: Xiaoyan Zhu, e-mail: zhuxiaoyanx@126.com Zhiqiang Meng, e-mail: mengzhq@gmail.com Keywords: bufalin, metastasis, HIF-1α, hepatocellular carcinoma, PI3K/AKT/mTOR Received: July 20, 2015 Accepted: January 06, 2016 Published: March 06, 2016 ABSTRACT It has been reported that there are multiple mechanisms by which bufalin could exert its antimetastatic effect. HIF-1α has been reported to be involved in tumor migration and invasion by regulating EMT. However, it is not known whether bufalin could exert the antimetastatic effect by modulating HIF-1α expression in hepatocellular carcinoma. In the present study, we aimed to evaluate the antimetastatic potential of bufalin in vivo and in vitro . Our results demonstrated that the liver/lung metastases were significantly reduced in bufalin-treated mice, as tested in the orthotopic transplanted and tail vein injection tumor models. Furthermore, the epithelial-to-mesenchymal transition (EMT) was inhibited in bufalin-treated tumors, as reflected the upregulation of E-cadherin, and downregulation of N-cadherin, vimentin, Snail. Similar results were observed in SMMC7721 cells treated with bufalin. Moreover, the transforming growth factor-β1 (TGF-β1)-induced EMT was also abrogated by bufalin. Mechanistically, our study demonstrated that hypoxia-inducible factor-1α (HIF-1α) played an important role in the antimetastatic effect of bufalin in hepatocellular carcinoma. Importantly, HIF-1α expression may be regulated through the inhibition of the PI3K/AKT/mTOR pathway. Taken together, our results suggest that bufalin suppresses hepatic tumor invasion and metastasis and that this process may be related to the PI3K/AKT/mTOR/ HIF-1α axis." @default.
- W2294409638 created "2016-06-24" @default.
- W2294409638 creator A5003930955 @default.
- W2294409638 creator A5031077714 @default.
- W2294409638 creator A5032470217 @default.
- W2294409638 creator A5035501418 @default.
- W2294409638 creator A5047297272 @default.
- W2294409638 creator A5050764830 @default.
- W2294409638 creator A5056336376 @default.
- W2294409638 creator A5077430901 @default.
- W2294409638 creator A5084985894 @default.
- W2294409638 date "2016-03-06" @default.
- W2294409638 modified "2023-10-02" @default.
- W2294409638 title "Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway" @default.
- W2294409638 cites W130174201 @default.
- W2294409638 cites W170574140 @default.
- W2294409638 cites W1760215417 @default.
- W2294409638 cites W1809990660 @default.
- W2294409638 cites W1954761903 @default.
- W2294409638 cites W1966802465 @default.
- W2294409638 cites W1968687296 @default.
- W2294409638 cites W1970319220 @default.
- W2294409638 cites W1991796034 @default.
- W2294409638 cites W2011810742 @default.
- W2294409638 cites W2014648810 @default.
- W2294409638 cites W2033526132 @default.
- W2294409638 cites W2039474933 @default.
- W2294409638 cites W2042248589 @default.
- W2294409638 cites W2067946566 @default.
- W2294409638 cites W2070741417 @default.
- W2294409638 cites W2071609983 @default.
- W2294409638 cites W2075466369 @default.
- W2294409638 cites W2076583198 @default.
- W2294409638 cites W2077462602 @default.
- W2294409638 cites W2078659604 @default.
- W2294409638 cites W2081010886 @default.
- W2294409638 cites W2083441068 @default.
- W2294409638 cites W2090912466 @default.
- W2294409638 cites W2094280155 @default.
- W2294409638 cites W2095510412 @default.
- W2294409638 cites W2105452584 @default.
- W2294409638 cites W2105604834 @default.
- W2294409638 cites W2106787323 @default.
- W2294409638 cites W2111689182 @default.
- W2294409638 cites W2113868465 @default.
- W2294409638 cites W2115860398 @default.
- W2294409638 cites W2117839432 @default.
- W2294409638 cites W2123413929 @default.
- W2294409638 cites W2129833757 @default.
- W2294409638 cites W2134361367 @default.
- W2294409638 cites W2135664375 @default.
- W2294409638 cites W2136286237 @default.
- W2294409638 cites W2140121036 @default.
- W2294409638 cites W2144248079 @default.
- W2294409638 cites W2145631502 @default.
- W2294409638 cites W2146644156 @default.
- W2294409638 cites W2164893560 @default.
- W2294409638 cites W2172002988 @default.
- W2294409638 cites W2176047031 @default.
- W2294409638 cites W2189093799 @default.
- W2294409638 cites W2303764417 @default.
- W2294409638 cites W2327922861 @default.
- W2294409638 cites W2402044391 @default.
- W2294409638 doi "https://doi.org/10.18632/oncotarget.7935" @default.
- W2294409638 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4991447" @default.
- W2294409638 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26958938" @default.
- W2294409638 hasPublicationYear "2016" @default.
- W2294409638 type Work @default.
- W2294409638 sameAs 2294409638 @default.
- W2294409638 citedByCount "91" @default.
- W2294409638 countsByYear W22944096382016 @default.
- W2294409638 countsByYear W22944096382017 @default.
- W2294409638 countsByYear W22944096382018 @default.
- W2294409638 countsByYear W22944096382019 @default.
- W2294409638 countsByYear W22944096382020 @default.
- W2294409638 countsByYear W22944096382021 @default.
- W2294409638 countsByYear W22944096382022 @default.
- W2294409638 countsByYear W22944096382023 @default.
- W2294409638 crossrefType "journal-article" @default.
- W2294409638 hasAuthorship W2294409638A5003930955 @default.
- W2294409638 hasAuthorship W2294409638A5031077714 @default.
- W2294409638 hasAuthorship W2294409638A5032470217 @default.
- W2294409638 hasAuthorship W2294409638A5035501418 @default.
- W2294409638 hasAuthorship W2294409638A5047297272 @default.
- W2294409638 hasAuthorship W2294409638A5050764830 @default.
- W2294409638 hasAuthorship W2294409638A5056336376 @default.
- W2294409638 hasAuthorship W2294409638A5077430901 @default.
- W2294409638 hasAuthorship W2294409638A5084985894 @default.
- W2294409638 hasBestOaLocation W22944096381 @default.
- W2294409638 hasConcept C121608353 @default.
- W2294409638 hasConcept C126322002 @default.
- W2294409638 hasConcept C143998085 @default.
- W2294409638 hasConcept C185592680 @default.
- W2294409638 hasConcept C190283241 @default.
- W2294409638 hasConcept C2777151579 @default.
- W2294409638 hasConcept C2778019345 @default.
- W2294409638 hasConcept C2779013556 @default.
- W2294409638 hasConcept C502942594 @default.